- Conditions
- Influenza, Human
- Interventions
- Flu shot text messages
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 734,383 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 191
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-small Cell Lung Cancer NSCLC
- Interventions
- Durvalumab, Placebo for Olaparib, Olaparib, Nab-paclitaxel+carboplatin, Gemcitabine+carboplatin, Pemetrexed+carboplatin, Gemcitabine+cisplatin, Pemetrexed+cisplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 9
- States / cities
- Bonita Springs, Florida • St. Petersburg, Florida • Tallahassee, Florida + 6 more
- Conditions
- Surgery, Non Diabetic Hyperglycemia
- Interventions
- glucose, insulin, and potassium (GIK), Crystalloid Infusion
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Myocarditis Acute
- Interventions
- Methylprednisolone, saline solution
- Drug
- Lead sponsor
- Niguarda Hospital
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 4
- States / cities
- San Diego, California • Houston, Texas • Charlottesville, Virginia + 1 more
- Conditions
- Systemic Sclerosis-Associated PAH
- Interventions
- Rituximab, Placebo, CMRI, prednisone, methylprednisolone, diphenhydramine, acetaminophen
- Biological · Other · Diagnostic Test + 1 more
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 17
- States / cities
- Stanford, California • Aurora, Colorado • Iowa City, Iowa + 13 more
- Conditions
- Rib Fractures
- Interventions
- Placebo Patch, 4% Lidocaine Patch
- Other · Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Wound Healing
- Interventions
- GSK1278863, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 7
- States / cities
- Castro Valley, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Osimertinib, Cisplatin, Carboplatin, Placebo, Pemetrexed
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 12
- States / cities
- Duarte, California • Irvine, California • San Francisco, California + 9 more
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
- Interventions
- Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
- Interventions
- mRNA COVID-19, IIV4, Placebo (saline)
- Biological · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 348 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Durham, North Carolina • Cincinnati, Ohio
- Conditions
- Diffuse Hemispheric Glioma, H3 G34-Mutant
- Interventions
- Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis, Nivolumab, Placebo Administration, Poly ICLC, Resection
- Biological · Procedure · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 13 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pain Management, Opioid Consumption
- Interventions
- Placebo, Oxycodone 5 mg, Multimodal Non-Opioid Analgesia
- Drug · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
- Interventions
- Exebacase, Placebo
- Drug
- Lead sponsor
- ContraFect
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 55
- States / cities
- Birmingham, Alabama • Orange, California • Sacramento, California + 47 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Placebo, Belimumab 200 mg SC, Standard therapy
- Biological · Drug
- Lead sponsor
- Human Genome Sciences Inc., a GSK Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 839 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 82
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 68 more
- Conditions
- Postoperative Pain
- Interventions
- Low Dose SKY0402, High Dose SKY0402, Placebo, Fentanyl via PCA, Bupivacaine via epidural
- Drug
- Lead sponsor
- Pacira Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 5
- States / cities
- Pasadena, California • Orlando, Florida • Houston, Texas + 1 more
- Conditions
- Heart Failure, Worsening Heart Failure (WHF)
- Interventions
- Placebo, R2R01
- Drug
- Lead sponsor
- River 2 Renal Corp.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 8
- States / cities
- Fairhope, Alabama • Fort Meyers, Florida • Hialeah, Florida + 5 more
- Conditions
- Psoriasis
- Interventions
- Guselkumab, Placebo
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Rochester, New York
- Conditions
- Myocardial Infarction
- Interventions
- Aliskiren, placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 820 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Novartis US, New Jersey
- Conditions
- Acute Kidney Injury, Ischemia Reperfusion Injury
- Interventions
- Valproic acid, Isotonic saline solution
- Drug
- Lead sponsor
- Westat
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 4
- States / cities
- San Francisco, California • Denver, Colorado • Dallas, Texas + 1 more
- Conditions
- Tophaceous Gout
- Interventions
- Rituximab
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Acute Ischemic Stroke
- Interventions
- Transcranial ultrasound as an adjunctive therapy to tPA, Standard of care tPA therapy for acute ischemic stroke
- Device · Drug
- Lead sponsor
- Cerevast Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Redmond, Washington
- Conditions
- Opioid Use Disorder
- Interventions
- AZD4041, Itraconazole, Buprenorphine, Buprenorphine / Naloxone, Hydromorphone, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Advanced Solid Tumors (Excluding Breast Cancer)
- Interventions
- TAS-102, Placebo
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Nintedanib (BIBF1120), Pemetrexed, B12, dexamethasone (or corticosteroid equivalent), placebo, Folic Acid
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 718 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 40
- States / cities
- Downy, California • Fountain Valley, California • Fullerton, California + 37 more